<DOC>
	<DOCNO>NCT00325728</DOCNO>
	<brief_summary>The purpose study determine efficacy ramelteon , daily ( QD ) , subject mild moderate Alzheimer 's Disease sleep disturbance</brief_summary>
	<brief_title>Efficacy Safety Ramelteon Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Epidemiological data 2005 show estimate 4.2 million people US suffer Alzheimer 's disease , often necessitate caregiver assistance , many case progress institutionalization . Subjects Alzheimer 's disease dementia frequently experience disturbed sleep pattern characterize insufficient nocturnal sleep excessive daytime napping , associate cognitive behavioral pathology impair daytime functioning , agitation , nocturnal wandering . Although causality sleep disturbance Alzheimer 's disease remain unclear ; research suggest fragment sleep associate behavioral disturbance could relate degeneration serotonergic noradrenergic innervation suprachiasmatic nucleus andsubsequent disruption melatonin secretion pattern . Additionally , research suggest melatonin level decrease patient Alzheimer 's disease In United States , ramelteon market treatment insomnia characterize difficulty sleep onset global development treatment transient , chronic insomnia circadian rhythm sleep disorder . It believe ramelteon work bind melatonin MT1/MT2 receptor suprachiasmatic nucleus inhibits fire specific neuron , think attenuate alert signal allows homeostatic mechanism express promote sleep . Study participation anticipate 11 week ( approximately 3 month ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Inclusion Criteria Clinical diagnosis dementia Alzheimer 's type ( Diagnostic Statistical Manual Mental Disorders , 4th Edition Revised ) probable Alzheimer 's disease National Institute Neurological Communicative Disorders Stroke/the Alzheimer 's Disease Related Disorders Association criterion . Female subject must postmenopausal . Stable residence plan move entire investigation period . Residing residence responsible spouse , family member , professional caregiver present night would agree assume role principal caregiver duration protocol period . Able ingest oral medication participate schedule evaluation . Clinical laboratory evaluation ( include clinical chemistry , hematology , urinalysis ) within reference range test designated laboratory unless result deem clinically significant investigator sponsor . Treatment medication nonexcluded medication concurrent medical condition stable 30 day prior screen visit medication ( ) investigator 's judgment , remain stable throughout duration study . MiniMental State Examination score 8 28 , inclusive . History great equal 2 sleep disorder behavior , occur least weekly two week screen . Actigraphy evidence show nighttime total sleep time le 7 hour per night base least 4 7 night complete actigraphy data collect singleblind , placebo runin period . Habitual bedtime 8 PM 12 AM . Exclusion Criteria Nonambulatory , wheel chair bound confine bed without consistent caregiver present night could function primary caregiver . Caregiver deem investigator unreliable supervise wear actigraphy , complete sleep log , administer medication proper time , bring subject schedule visit answer question regard subject 's condition medication use . Lacks mobile upper extremity attach actigraphy . Currently participate participate another clinical study within past 30 day . Demonstrates unwillingness abstain caffeine 2:00 PM duration clinical trial participation . Demonstrates unwillingness comply maximum limit two alcoholic drink per day one alcoholic drink 6:00 PM duration protocol . Uses tobacco product product nightly awakening may interfere sleep wake cycle . History drug abuse test positive presence illicit drug . Donated 400 mL blood within 90 day precede begin study . Diastolic blood pressure great 95 mm Hg systolic pressure great 160 mm Hg . Body mass index great 36 . Alanine transaminase level great two time upper limit normal , active liver disease , jaundice clinically significant abnormal laboratory finding determine investigator . History hypersensitivity allergy Ramelteon melatonin . History contraindication note Ramelteon label History significant stroke vascular dementia . History severe renal dysfunction disease . History cancer , basal cell carcinoma , remission least 5 year prior first dose study drug . ( This criterion include subject basal cell Stage 1 squamous cell carcinoma skin . ) Any clinically significant movement disorder include limited : akinesia , periodic limb movement disorder , restless leg syndrome , epilepsy , uncontrolled Parkinson 's disease , severe benign prostatic hyperplasia , cardiac asthma , chronic obstructive pulmonary disease . Rapid eye movement behavior disorder sleep apnea . Any pain syndrome affecting sleep . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Fluvoxamine Melatonin Rifampicin</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Chronic Insomnia</keyword>
	<keyword>Sleep Initiation Maintenance Disorder</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Alzheimer disease</keyword>
</DOC>